April 29th, at 6pm Health Day blood donation campaign free invitation for RCDE – Valencia Mejor sin Cáncer Public Health Agency, the Blood and Tissue Bank, the Red Cross, the Spanish Association against Cancer, IDIBELL, the Spanish Society of Pharmacists and Farmapericos, the Catalan Federation of Adapted Sports and Afrucat
IDIBELL and ICO researchers take part in RCD Espanyol’s Heath Day Read More »
Researchers from the transformation and metastasis group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Eva González-Suárez, have been able to recreate and characterize the process of acquisition of resistance to chemotherapy in orthotopic animal models of breast cancer, unveiling the possibility of reversing this resistance after a period of rest from the
Depolarization causes the formation of a ternary complex between GlialCAM, MLC1 and ClC-2 in astrocytes: implications in megalencephalic leukoencephalopathy.
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) participated in a study published recently in the by the journal Investigative Dermatology, entitled “AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK / ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact
IDIBELL researchers look for new drugs against melanoma Read More »
The Department of Health has issued the final resolution of the first call for research grants linked to the Strategic Plan for Research and Innovation in Health (PERIS) 2016-2020. Researchers from the University Hospital of Bellvitge (HUB), the Catalan Institute of Oncology (ICO) and the University of Barcelona (UB) and their research projects, managed through
Bellvitge research receives 1 million euros in PERIS 2016-2020 funding Read More »
